Trial Profile
A Single Arm, Open-label, Phase IIb Study to Assess the Efficacy and Safety of the Combination of Cediranib and Olaparib Tablets in Women With Recurrent Platinum Resistant Epithelial Ovarian Cancer, Including Fallopian Tube and/or Primary Peritoneal Cancer Who do Not Carry a Deleterious or Suspected Deleterious Germline BRCA Mutation
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Aug 2022
Price :
$35
*
At a glance
- Drugs Cediranib (Primary) ; Olaparib (Primary)
- Indications Carcinoma; Endometrial cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Acronyms CONCERTO
- Sponsors AstraZeneca
- 02 Aug 2022 Results published in the Clinical Cancer Research
- 01 Jun 2021 Status changed from active, no longer recruiting to completed.
- 18 Jan 2021 Planned End Date changed from 31 Dec 2020 to 31 Dec 2021.